Welcome to our dedicated page for Daxor news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor (Nasdaq: DXR) announces the expansion of its blood volume analysis (BVA) technology to three new facilities. The company's ezBVA lab service, a CLIA-certified facility providing next-day results, is spearheading growth and broader market adoption. Recent sales wins include:
- A leading medical center in Georgia adopting ezBVA Lab service
- A North Carolina hospital purchasing a blood volume analyzer
- A top-rated Central Florida hospital implementing ezBVA Lab service
Daxor anticipates accelerated sales growth for the rest of the year. The company's Sr. VP of Commercialization and Customer Experience, Jean Oertel, emphasized that their diagnostic solution helps healthcare facilities enhance patient care while managing expenses. The increasing adoption of Daxor's BVA technology highlights its critical impact on advancing treatment effectiveness for fluid management.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has been awarded a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This funding will support the integration of hematocrit measurement into a future generation Blood Volume Analyzer (BVA).
The upgrade aims to streamline the BVA test by eliminating the need for third-party hematocrit testing devices. This marks Daxor's eighth SBIR award, demonstrating the DHA's ongoing commitment to advancing next-generation medical technologies. The company's goal is to make blood volume measurement faster and easier in various settings, from bedside to clinical testing labs and combat zones.
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri, a 300-bed Covenant Health affiliate, and a leading South Texas teaching hospital and Level 1 trauma center. CEO Michael Feldschuh highlighted that strategic investments in sales and marketing are driving growth, with further developments expected in the year's second half.
Daxor (Nasdaq: DXR) will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22, 2024, at the Rosen Shingle Creek Resort in Orlando, Florida. The company will showcase its BVA-100™ Guided-Care technology, which provides precise blood volume analysis to improve heart failure management. Daxor claims that this technology can reduce hospital stays, 30-day readmissions, and mortality rates, potentially transforming cardiovascular care. The event offers a platform for Daxor to present evidence supporting these benefits.
Daxor (Nasdaq: DXR) has appointed Dr. John L. Jefferies as Chief Medical Officer. Dr. Jefferies, an esteemed cardiologist with extensive clinical and commercial experience, will guide Daxor's strategic and clinical affairs. His role aims to accelerate the adoption of Daxor's diagnostic solutions in clinical practice, driving growth and collaboration with healthcare professionals. Dr. Jefferies brings a robust background in heart failure, cardiomyopathies, genetics, and AI, having published over 300 peer-reviewed manuscripts and served in numerous academic and leadership roles.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.